Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Fact checked by Jennifer Klump Although respiratory syncytial virus (RSV) is often associated with children, adults can also get it. RSV usually causes mild, cold-like symptoms such as cough, ...

Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...

8月3日， 沃森生物 公告显示，公司与复旦大学、上海蓝鹊生物联合研发的RSV mRNA疫苗，已正式获国家药监局临床试验申请受理。这款基于自主研发mRNA技术平台的疫苗，瞄准的是预防RSV感染引起的下呼吸道相关疾病—— ...

截至2025年8月4日收盘，沃森生物(300142)报收于13.09元，上涨4.05%，换手率5.04%，成交量78.66万手，成交额10.12亿元。 当日关注点 ...